- Index hide
According to Statista, The number of people aged 65 and older with Alzheimer’s is expected to rise to 8.5 million by the year 2030.
Statista estimated that by the year 2020 around 6.1 million people over the age of 65 suffered from Alzheimer’s disease.
Data presented at the annual Alzheimer’s Disease Clinical Trials meeting in San Francisco and published in the New England Journal of Medicine, show that treatment with the drug was able to somewhat slow the progression of cognitive decline in people in the early stages of the disease. However, it also caused some patients to experience swelling or bleeding in the brain.
It should be noted that this drug has been shown to be effective in stopping the progression in the early stages of the disease, which is why many patients would be excluded without a revolutionary method to detect Alzheimer’s disease early.
What was the method used for the study?
According to the study, An 18-month, multicenter, double-blind, Phase 3 trial was conducted in people 50 to 90 years of age with early Alzheimer’s disease. Where participants were assigned a 1:1 ratio to receive intravenous lecanemab or placebo.
A total of 1,795 participants were enrolled, with 898 assigned to receive lecanemab and 897 to receive placebo. Results of the trial showed that in 698 participants, there were greater reductions in brain amyloid burden with the drug lecanemab than with placebo in Alzheimer’s patients.
However, Lecanemab caused infusion-related reactions in 26.4% of participants and amyloid-related imaging abnormalities with edema or effusions in 12.6%. according to the published study.
This result was supported by secondary measures in the trial, including three other cognitive tests, bolstering the possibility that the drug has a real effect, the experts said. In addition, across all measures, patients began to show a slower decline several months after starting lecanemab, and the rate slowed further during the 18-month trial.
Related notes: